Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report

Abstract

Homozygous loss-of-function mutations in optineurin (OPTN) are a rare cause of amyotrophic lateral sclerosis (ALS), whereas heterozygous loss-of-function mutations have been suggested to increase ALS disease risk. We report a patient with ALS and frontotemporal dementia (FTD) from the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium carrying compound heterozygous loss-of-function variants in OPTN. Quantitative real-time mRNA expression analyses revealed a 75–80% reduction in OPTN expression in blood in the OPTN carrier as compared to controls, suggesting at least partial nonsense-mediated decay of the mutant transcripts. This case report illustrates the diverse inheritance patterns and variable clinical presentations associated with OPTN mutations, and underscores the importance of complete OPTN gene screening in patients with ALS and related disorders, especially in the context of clinical genetic testing.

Keywords:

• Amyotrophic lateral sclerosis
• frontotemporal dementia
• optineurin
• compound heterozygous
• mutation

Acknowledgements

The authors would like to thank the patient and his family. The CReATe consortium (U54NS092091) is part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS.

Declaration of interest

The authors report no conflicts of interest.

This consortium is funded through collaboration between NCATS and the NINDS. CReATe is also supported by the ALS Association [grants 17-LGCA-331 and 16-TACL-242]. This work was further supported by NIH/NINDS grant [R35NS097261].

Additional information

Funding

This consortium is funded through collaboration between NCATS and the NINDS. CReATe is also supported by the ALS Association [grants 17-LGCA-331 and 16-TACL-242]. This work was further supported by NIH/NINDS grant [R35NS097261].